PARK INNOVAARE, the innovation park at the Paul Scherrer Institute (PSI), the largest engineering and scientific research institute in Switzerland, attaches great importance to research on modern diagnostic methods and new, more effective therapies against cancer.
Four startups residing at the innovation park are dedicated to the fight against difficult to diagnose or difficult to treat cancers. All four are active in different areas of cancer research.
Winner of the Swiss Technology Award in 2017, GratXray is working on new imaging techniques for breast cancer diagnosis. Its work builds on a technology that was developed at PSI.
leadXpro is researching and discovering new medical compounds for tumours in tissues that are difficult to reach with conventional substances. “Examples for this include pancreatic cancer and brain tumours” for which “totally new therapeutic approaches are possible,” leadXpro CEO Michael Hennig said in a statement.
Advanced Accelerator Technology is developing a proton therapy for the treatment of ocular melanoma, which also was developed at PSI. The company provides beam diagnostics components used to monitor the precision of the proton beam.
Last but not least is PharmaTRAYCE, which is developing tracers that can navigate towards very specific areas of the human body. Consisting of a radionuclide and a carrier molecule, its tracers are able to provide oncologists with extremely precise information about the location and nature of a tumour.
